Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.
Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.
As scientists unravel how sleep benefits the body, a study in mice is highlighting the potential pitfalls of using Ambien and other sleeping pills.
Even if that’s a green flag, patients should be educated about potential cardiac side effects and signs to watch for. Dose adjustments and limiting the duration of treatment can help reduce the risk.
1 The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China 2 Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China A 42 year-old ...
AD patients prescribed dupilumab exhibited a lower risk of psychiatric and sleep disorders, with the effect being more evident within the Black or African American subgroup. After propensity score ...
A generic version of the drug isn’t currently available. Like most drugs, Mounjaro may cause mild or serious side effects. The lists that follow describe some of the more common side effects ...
"Some researchers believe that repeated exposure to false information can cause people to not get vaccinated, while others believe the effect is relatively weak because it would only allow them to ...